리팍시민 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "리팍시민" in Korean language version.

refsWebsite

Global rank Korean rank

15nih.gov

4^th place

14doi.org

2^nd place

3^rd place

4semanticscholar.org

11^th place

310^th place

1archive.org

6^th place

18^th place

1medscape.com

719^th place

424^th place

1drugbank.ca

4,294^th place

1,811^th place

archive.org

Lawrence KR, Klee JA (August 2008). “Rifaximin for the treatment of hepatic encephalopathy”. 《Pharmacotherapy》 28 (8): 1019–1032. doi:10.1592/phco.28.8.1019. PMID 18657018. S2CID 25662917. Free full text with registration at Medscape.

doi.org

dx.doi.org

Koo HL, DuPont HL (January 2010). “Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases”. 《Current Opinion in Gastroenterology》 26 (1): 17–25. doi:10.1097/MOG.0b013e328333dc8d. PMC 4737517. PMID 19881343.
DuPont HL (July 2007). “Therapy for and prevention of traveler's diarrhea”. 《Clinical Infectious Diseases》. 45 Suppl 1 (Suppl 1): S78–S84. doi:10.1086/518155. PMID 17582576.
Kane JS, Ford AC (2016). “Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome”. 《Expert Review of Gastroenterology & Hepatology》 10 (4): 431–442. doi:10.1586/17474124.2016.1140571. PMID 26753693. S2CID 13607138.
Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A (July 2016). “Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation”. 《Expert Opinion on Drug Safety》 15 (7): 983–991. doi:10.1080/14740338.2016.1186639. PMID 27149541. S2CID 25426888.
Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD, 외. (April 2018). “Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition”. 《Journal of Neurogastroenterology and Motility》 24 (2): 197–215. doi:10.5056/jnm17145. PMC 5885719. PMID 29605976.
Iorio N, Malik Z, Schey R (2015). “Profile of rifaximin and its potential in the treatment of irritable bowel syndrome”. 《Clinical and Experimental Gastroenterology》 8: 159–167. doi:10.2147/CEG.S67231. PMC 4467648. PMID 26089696.
Lawrence KR, Klee JA (August 2008). “Rifaximin for the treatment of hepatic encephalopathy”. 《Pharmacotherapy》 28 (8): 1019–1032. doi:10.1592/phco.28.8.1019. PMID 18657018. S2CID 25662917. Free full text with registration at Medscape.
Kimer N, Krag A, Gluud LL (March 2014). “Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy”. 《Patient Preference and Adherence》 8: 331–338. doi:10.2147/PPA.S41565. PMC 3964161. PMID 24672227.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, 외. (August 2014). “Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver”. 《Hepatology》 60 (2): 715–735. doi:10.1002/hep.27210. PMID 25042402. S2CID 3155213.
Piccin A, Gulotta M, di Bella S, Martingano P, Crocè LS, Giuffrè M (February 2023). “Diverticular Disease and Rifaximin: An Evidence-Based Review”. 《Antibiotics》 12 (3): 443. doi:10.3390/antibiotics12030443. PMC 10044695 |pmc= 값 확인 필요 (도움말). PMID 36978310.
Triantafyllou K, Sioulas AD, Giamarellos-Bourboulis EJ (2015). “Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome”. 《Mini Reviews in Medicinal Chemistry》 16 (3): 186–192. doi:10.2174/1389557515666150722105340. PMID 26202193.
Weinstock LB, Steinhoff M (May 2013). “Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin”. 《Journal of the American Academy of Dermatology》 68 (5): 875–876. doi:10.1016/j.jaad.2012.11.038. PMID 23602178.
Pimentel M (January 2016). “Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea”. 《Alimentary Pharmacology & Therapeutics》. 43 Suppl 1 (Suppl 1): 37–49. doi:10.1111/apt.13437. PMID 26618924.
Lee KJ (October 2015). “Pharmacologic Agents for Chronic Diarrhea”. 《Intestinal Research》 13 (4): 306–312. doi:10.5217/ir.2015.13.4.306. PMC 4641856. PMID 26576135.

drugbank.ca

“Rifaximin”. 《DrugBank》. 2017년 3월 22일.

medscape.com

Lawrence KR, Klee JA (August 2008). “Rifaximin for the treatment of hepatic encephalopathy”. 《Pharmacotherapy》 28 (8): 1019–1032. doi:10.1592/phco.28.8.1019. PMID 18657018. S2CID 25662917. Free full text with registration at Medscape.

nih.gov

ncbi.nlm.nih.gov

Koo HL, DuPont HL (January 2010). “Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases”. 《Current Opinion in Gastroenterology》 26 (1): 17–25. doi:10.1097/MOG.0b013e328333dc8d. PMC 4737517. PMID 19881343.
DuPont HL (July 2007). “Therapy for and prevention of traveler's diarrhea”. 《Clinical Infectious Diseases》. 45 Suppl 1 (Suppl 1): S78–S84. doi:10.1086/518155. PMID 17582576.
Kane JS, Ford AC (2016). “Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome”. 《Expert Review of Gastroenterology & Hepatology》 10 (4): 431–442. doi:10.1586/17474124.2016.1140571. PMID 26753693. S2CID 13607138.
Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A (July 2016). “Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation”. 《Expert Opinion on Drug Safety》 15 (7): 983–991. doi:10.1080/14740338.2016.1186639. PMID 27149541. S2CID 25426888.
Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD, 외. (April 2018). “Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition”. 《Journal of Neurogastroenterology and Motility》 24 (2): 197–215. doi:10.5056/jnm17145. PMC 5885719. PMID 29605976.
Iorio N, Malik Z, Schey R (2015). “Profile of rifaximin and its potential in the treatment of irritable bowel syndrome”. 《Clinical and Experimental Gastroenterology》 8: 159–167. doi:10.2147/CEG.S67231. PMC 4467648. PMID 26089696.
Lawrence KR, Klee JA (August 2008). “Rifaximin for the treatment of hepatic encephalopathy”. 《Pharmacotherapy》 28 (8): 1019–1032. doi:10.1592/phco.28.8.1019. PMID 18657018. S2CID 25662917. Free full text with registration at Medscape.
Kimer N, Krag A, Gluud LL (March 2014). “Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy”. 《Patient Preference and Adherence》 8: 331–338. doi:10.2147/PPA.S41565. PMC 3964161. PMID 24672227.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, 외. (August 2014). “Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver”. 《Hepatology》 60 (2): 715–735. doi:10.1002/hep.27210. PMID 25042402. S2CID 3155213.
Piccin A, Gulotta M, di Bella S, Martingano P, Crocè LS, Giuffrè M (February 2023). “Diverticular Disease and Rifaximin: An Evidence-Based Review”. 《Antibiotics》 12 (3): 443. doi:10.3390/antibiotics12030443. PMC 10044695 |pmc= 값 확인 필요 (도움말). PMID 36978310.
Triantafyllou K, Sioulas AD, Giamarellos-Bourboulis EJ (2015). “Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome”. 《Mini Reviews in Medicinal Chemistry》 16 (3): 186–192. doi:10.2174/1389557515666150722105340. PMID 26202193.
Weinstock LB, Steinhoff M (May 2013). “Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin”. 《Journal of the American Academy of Dermatology》 68 (5): 875–876. doi:10.1016/j.jaad.2012.11.038. PMID 23602178.
Pimentel M (January 2016). “Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea”. 《Alimentary Pharmacology & Therapeutics》. 43 Suppl 1 (Suppl 1): 37–49. doi:10.1111/apt.13437. PMID 26618924.
Lee KJ (October 2015). “Pharmacologic Agents for Chronic Diarrhea”. 《Intestinal Research》 13 (4): 306–312. doi:10.5217/ir.2015.13.4.306. PMC 4641856. PMID 26576135.

dailymed.nlm.nih.gov

“Xifaxan- rifaximin tablet”. 《DailyMed》. 2019년 10월 1일. 2020년 11월 11일에 확인함.

semanticscholar.org

api.semanticscholar.org

Kane JS, Ford AC (2016). “Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome”. 《Expert Review of Gastroenterology & Hepatology》 10 (4): 431–442. doi:10.1586/17474124.2016.1140571. PMID 26753693. S2CID 13607138.
Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A (July 2016). “Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation”. 《Expert Opinion on Drug Safety》 15 (7): 983–991. doi:10.1080/14740338.2016.1186639. PMID 27149541. S2CID 25426888.
Lawrence KR, Klee JA (August 2008). “Rifaximin for the treatment of hepatic encephalopathy”. 《Pharmacotherapy》 28 (8): 1019–1032. doi:10.1592/phco.28.8.1019. PMID 18657018. S2CID 25662917. Free full text with registration at Medscape.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, 외. (August 2014). “Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver”. 《Hepatology》 60 (2): 715–735. doi:10.1002/hep.27210. PMID 25042402. S2CID 3155213.